Skip to content
    LFST
    Earnings call· Dec 2025(Q4 FY25)

    LifeStance Health Group Q4 FY25 earnings call LFST

    Feb 25, 2026 Source

    Executive summary

    LifeStance Health Q4 FY25 — Record Performance and Accelerated Margin Expansion

    LifeStance Health delivered an exceptional Q4 and full-year FY25, exceeding all guided metrics with robust organic growth and significant margin expansion. The company achieved positive net income and record free cash flow ahead of schedule, driven by strong clinician productivity and strategic technology investments. Management is confident in continued growth and operating leverage, targeting mid-teens adjusted EBITDA margins by FY28, supported by a new EHR implementation and a recently authorized share repurchase program.

    Highlights

    5

    • Full-year revenue grew 14% year-over-year to $1.424 billion.

    • Full-year adjusted EBITDA increased 32% year-over-year to $158 million, with margins expanding 150 basis points to 11.1%.

    • Achieved positive net income and earnings per share for the full year, one year ahead of expectations.

    • Generated robust free cash flow of $110 million for the full year, a record for the company.

    • Clinician productivity improved by a remarkable 7% in the second half of the year.

    Concerns

    2

    • Competitive environment for clinicians

    • M&A valuation expectations

    Guidance & targets

    13
    CategoryTargetConfidence
    Full-year 2026 Revenue
    $1.615 billion to $1.655 billion
    high materiality
    High
    Full-year 2026 Center Margin
    $526 million to $550 million
    medium materiality
    High
    Full-year 2026 Adjusted EBITDA
    $185 million to $205 million
    high materiality
    High
    Q1 2026 Revenue
    $380 million to $400 million
    medium materiality
    High
    Q1 2026 Center Margin
    $118 million to $132 million
    medium materiality
    High
    Q1 2026 Adjusted EBITDA
    $39 million to $45 million
    medium materiality
    High
    Long-term Revenue Growth
    mid-teens
    high materiality
    High
    Long-term Adjusted EBITDA Margin
    mid-teens
    high materiality
    High
    New Centers
    20 to 30
    medium materiality
    High
    EHR Implementation Cash Usage
    $20 million to $30 million
    medium materiality
    High
    Stock-based Compensation
    $60 million to $70 million
    low materiality
    High
    Stock-based Compensation Reduction
    $10 million per year
    low materiality
    High
    Specialty Services Revenue
    $70 million
    medium materiality
    High

    Operational metrics

    25
    Total clinicians
    8,040+9% YoY
    Q4 FY25
    Net clinician adds
    44
    Q4 FY25

    Intentional effort to balance existing capacity and new hires.

    Net clinician adds
    657
    FY25
    Visits per average clinician
    7%YoY
    Q4 FY25

    Improvement driven by operational initiatives.

    Patient Net Promoter Score
    84
    FY25
    Average Google ratings
    4.7
    FY25

    Across over 570 centers.

    Revenue per visit
    $160roughly flat YoY
    Q4 FY25

    Modestly ahead of expectations.

    Center margin
    33%+15% YoY
    Q4 FY25

    Exceeded expectations due to revenue beat and slightly lower spend.

    Adjusted EBITDA margin
    12.8%+49% YoY
    Q4 FY25

    Highest in company history as a public company.

    Adjusted EBITDA margin
    11.1%+150 bps YoY
    FY25
    Cash position
    $249 million
    Q4 FY25
    Net long-term debt
    $266 million
    Q4 FY25
    Undrawn revolver capacity
    $100 million
    Q4 FY25
    Net leverage
    0.2x
    Q4 FY25
    Gross leverage
    1.8x
    Q4 FY25
    Share repurchase program authorization
    $100 million
    announced Q4 FY25

    Funded with cash on hand. Highly efficient way to deploy capital and create long-term shareholder value.

    Revenue growth (long-term)
    mid-teens
    Beyond FY26

    Based on low-to-mid-single-digit annual rate growth and low-double-digit volume growth.

    Revenue per visit growth (long-term)
    low-to-mid-single-digit
    Annual
    Visit volume growth (long-term)
    low-double-digit
    Annual
    EHR implementation cash usage
    $20 million to $30 million
    2026-2027

    Most costs will be capitalized or adjusted in EBITDA as nonrecurring.

    Stock-based compensation
    $60 million to $70 million
    FY26
    Stock-based compensation reduction
    $10 million
    per year

    Due to sunsetting clinician stock-based incentive program.

    Specialty services revenue
    $70 million+40% YoY
    FY26 target

    Expected to grow faster than core business, contributing to growth and margins. Low capital intensity, leveraging existing centers.

    New patient acquisition cost
    2%
    ongoing

    Efficient model due to referral programs with medical practices.

    AI tools phone call conversion improvement
    5%
    FY25

    Improvement in converting inquiries to booked appointments.

    Industry KPIs

    3
    MetricValueDetails
    Utilization trendsNearly 9 millionvisits
    Membership covered lives by lineOver 1 millionpatients
    Adjusted EPS EBITDA leverage guidancePositive

    Deals & partnerships

    2
    LifeStance Health Group, Inc.Share repurchase program authorization$100 million

    Board of Directors authorized a share repurchase program up to $100 million of outstanding shares, funded with cash on hand.

    CalmReferral partnership for new patient volume

    Still early days, working to optimize the partnership. Currently providing new patient volume but not yet meaningful. Expected to attract a younger, more digitally native demographic.

    Risks & headwinds

    2
    Competitive environment for cliniciansongoing

    unquantified

    Mitigation: General efforts to improve clinician satisfaction and retention; leveraging existing capacity first.

    M&A valuation expectationsongoing

    unquantified

    Mitigation: Targeting smaller tuck-in opportunities for geographic expansion where valuations are more appropriate, avoiding larger companies with dislocated expectations.

    What to watch in Q1 FY26

    5

    Clinician productivity

    next quarter
    Current7% improvement in H2 FY25
    TargetContinued complementary benefit to visit growth

    Why it matters

    Sustained productivity is key to leveraging existing clinician capacity and achieving growth targets, contributing to operating leverage.

    The growth algorithm of that is still -- we expect low-double-digit visit growth, and that's going to come primarily from net clinician adds with some complementary benefit from productivity.

    Q&A highlights

    7

    How is the inflection in clinician productivity from H2 FY25 impacting the business, and how durable are these improvements?

    The productivity initiatives, including scheduling improvements and cash incentives, have shown durability from Q3 to Q4 and into 2026. While productivity is complementary, the primary driver for 2026 revenue growth (15%) will still be net clinician adds, with low-double-digit visit growth expected.

    “The growth algorithm of that is still -- we expect low-double-digit visit growth, and that's going to come primarily from net clinician adds with some complementary benefit from productivity.”

    asked by Craig Hettenbach · answered by David Bourdon

    2 min read5 chapters

    Detailed Narrative

    01

    Operational Excellence & Productivity

    LifeStance achieved a remarkable 7% improvement in clinician productivity in the second half of FY25, driven by several initiatives. These included process improvements in clinician scheduling, a new cash incentive program for clinicians tied to quality and productivity, and enhancements to patient access through shortened booking lead times and improved conversion of phone calls to booked appointments. These initiatives have delivered consistently improved and durable results, reinforcing the company's ability to better utilize existing clinician capacity.

    02

    Strategic Technology & AI Adoption

    In FY25, LifeStance intentionally applied Digital and AI solutions to support patient access, clinician experience, and operational efficiency. Examples include implementing AI technology for new patient phone booking, which improved conversion rates by 5%, and piloting AI-assisted documentation for clinicians, showing reduced administrative burden. Digital and AI tools were also instrumental in revenue cycle management, such as digital patient check-in and robotic process automation, leading to strong cash collections.

    03

    Foundational EHR Transition

    The company completed its EHR discovery process and decided to transition to a new best-in-class vendor. This is a foundational step for advancing the long-term operating model, positioning the business for continued scale. The new EHR is expected to improve clinician workflows, patient experience, clinical outcomes, and interoperability, which will benefit growing health system partnerships. Implementation will begin in 2026, with the transition to the new EHR expected during 2027, with an estimated cash usage of $20 million to $30 million over 2026-2027.

    04

    Growth Drivers & Capital Allocation

    LifeStance continues to focus on attracting new patients through investments in provider and partner referrals, including a new operating model for local market support and an expanded care matching pilot. Specialty services, such as SPRAVATO and TMS for treatment-resistant depression, are targeted to reach $70 million in revenue for 2026, representing a 40% increase. The company also authorized a $100 million share repurchase program, funded by cash on hand, while maintaining an active pipeline for disciplined M&A focused on geographic expansion.

    05

    Financial Strength & Long-Term Outlook

    LifeStance demonstrated strong financial performance with $110 million in free cash flow for FY25, a cash position of $249 million, and low leverage ratios (0.2x net, 1.8x gross). The company expects to generate meaningful positive free cash flow again in FY26. Management reiterated its long-term outlook for mid-teens revenue growth beyond 2026 and now expects to reach mid-teens adjusted EBITDA margins by fiscal year 2028, underscoring confidence in its platform and favorable macro mental health trends.

    AI-generated summary of the company’s earnings call. Not investment advice.